Ovarian Cancer Pipeline Outlook, FDA Approvals, Clinical Trials and Companies 2024 (Updated)

DelveInsight's, "Ovarian Cancer Pipeline Insight 2024" report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in the Ovarian Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Ovarian Cancer Pipeline Report

* DelveInsight's Ovarian Cancer pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for Ovarian Cancer treatment.
* The leading Ovarian Cancer Companies working in the market include Allarity Therapeutics, OSE Immunotherapeutic, Cristal Therapeutics, Bristol-Myers Squibb, Ono Pharmaceuticals, Merck & Co., Aravive Biologics, Mersana Therapeutics, Clovis Oncology, Verastem Oncology, Gradalis, AbbVie, Elevation Oncology, OncoQuest Pharmaceuticals (CanariaBio), Alkermes, Hoffman-la Roche, AstraZeneca, MSD, GlaxoSmithKline, IMV, Corcept Therapeutics and others.
* Promising Ovarian Cancer Therapies in the various stages of development include SAR245409, Karenitecin, Topotecan, OTL38, Magrolimab, Avelumab, and others.
* May 2024:- Bristol-Myers Squibb- A Phase 2 Open-label Randomized Study of Farletuzumab Ecteribulin (MORAb-202), a Folate Receptor Alpha-targeting Antibody-drug Conjugate, Versus Investigator's Choice Chemotherapy in Women With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. The purpose of the study is to assess the safety, tolerability, and efficacy of farletuzumab ecteribulin (MORAb-202) and compare it to Investigator's choice (IC) chemotherapy in female participants with platinum-resistant HGS ovarian, primary peritoneal, or fallopian tube cancer.
* April 2024:- L-Nutra Inc.- This study evaluates how lifestyle modifications that may be made to manage chemotherapy side effects in patients with gynecologic malignancies. The investigators will focus on patients undergoing chemotherapy for gynecologic malignancies. These patients will be assigned to no dietary restriction (control group) or a 5-day fasting mimicking diet (FMD by L-Nutra) for three days prior to, the day of, and one day following chemotherapy treatments (treatment group). The investigators aim to evaluate the feasibility of a fasting mimicking diet in addition to its metabolic effects on the body, patient reported side effects, patient quality of life, deviations or delays in treatment plans, and hospital admissions.
* April 2024:- Sarah K.Lynam MD- Efficacy of Oral Regorafenib Combined With Intra-muscular Injection of Fulvestrant in Patients With Recurrent Low-grade Serous Ovarian Cancer: A Phase II Single Arm Trial. Regorafenib is an investigational drug that works by interrupting the rapid and uncontrolled growth of cancer cells by stopping the signals that tell the cancer cells to grow and the ability of the cancer cells to form new blood vessels which they need to be able to grow.

Request a sample and discover the recent advances in Ovarian Cancer @ Ovarian Cancer Pipeline Outlook Report [https://www.delveinsight.com/sample-request/ovarian-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Ovarian Cancer Overview

Ovarian cancer is the leading cause of death in women diagnosed with gynecological cancers. It is also the fifth most frequent cause of death in women, in general. Most of the cases are diagnosed at an advanced stage, which leads to poor outcomes of this disease. Ovarian cancer can be further classified into two subtypes- Type I or Type II tumors, the latter being a more fatal variant, thought to be caused by continuous ovarian cycles leading to inflammation and endometriosis. Type I tumor includes low-grade serous, endometrioid, clear-cell, and mucinous carcinomas, with the rare subtypes being seromucinous and Brenner tumors. Type I tumors mostly arise from atypical proliferative (borderline) tumors.

Ovarian Cancer Emerging Drugs Profile

* Atezolizumab: Genentech
* Tisotumab Vedotin: Genmab
* SON-1010: Sonnet Biotherapeutics
* DS-6000a: Daiichi Sankyo Company

Learn more about Ovarian Cancer in clinical trials @ Ovarian Cancer Drugs [https://www.delveinsight.com/sample-request/ovarian-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Ovarian Cancer Therapeutics Assessment

There are approx. 180+ Ovarian Cancer companies which are developing the Ovarian Cancer therapies. The Ovarian Cancer companies which have their Ovarian Cancer drug candidates in the most advanced stage, i.e. phase III include, Genentech.

DelveInsight's Ovarian Cancer pipeline report covers around 200+ products under different phases of clinical development like

* Late stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I) along with the details of
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates

Discover more about Ovarian Cancer in development @ Ovarian Cancer Clinical Trials [https://www.delveinsight.com/sample-request/ovarian-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Ovarian Cancer Companies

Allarity Therapeutics, OSE Immunotherapeutic, Cristal Therapeutics, Bristol-Myers Squibb, Ono Pharmaceuticals, Merck & Co., Aravive Biologics, Mersana Therapeutics, Clovis Oncology, Verastem Oncology, Gradalis, AbbVie, Elevation Oncology, OncoQuest Pharmaceuticals (CanariaBio), Alkermes, Hoffman-la Roche, AstraZeneca, MSD, GlaxoSmithKline, IMV, Corcept Therapeutics and others.

Ovarian Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical

Ovarian Cancer Products have been categorized under various Molecule types such as

* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy

To know more about Ovarian Cancer, visit @ Ovarian Cancer Segmentation [https://www.delveinsight.com/sample-request/ovarian-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Ovarian Cancer Pipeline Report

* Coverage- Global
* Ovarian Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Ovarian Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* Ovarian Cancer Companies- Allarity Therapeutics, OSE Immunotherapeutic, Cristal Therapeutics, Bristol-Myers Squibb, Ono Pharmaceuticals, Merck & Co., Aravive Biologics, Mersana Therapeutics, Clovis Oncology, Verastem Oncology, Gradalis, AbbVie, Elevation Oncology, OncoQuest Pharmaceuticals (CanariaBio), Alkermes, Hoffman-la Roche, AstraZeneca, MSD, GlaxoSmithKline, IMV, Corcept Therapeutics and others.
* Ovarian Cancer Therapies- SAR245409, Karenitecin, Topotecan, OTL38, Magrolimab, Avelumab, and others.

For further information on the Ovarian Cancer Pipeline Therapeutics, reach out @ Ovarian Cancer Products Development [https://www.delveinsight.com/sample-request/ovarian-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Ovarian Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Ovarian Cancer- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Atezolizumab: Genentech
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Tisotumab Vedotin: Genmab
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* DS-6000a: Daiichi Sankyo Company
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Product Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Ovarian Cancer Key Companies
* Ovarian Cancer Key Products
* Ovarian Cancer- Unmet Needs
* Ovarian Cancer- Market Drivers and Barriers
* Ovarian Cancer- Future Perspectives and Conclusion
* Ovarian Cancer Analyst Views
* Ovarian Cancer Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=ovarian-cancer-pipeline-outlook-fda-approvals-clinical-trials-and-companies-2024-updated]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.